Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RIVAL: Opdivo in Veterans With Lung Cancer
NCT06275360Phase 2Recruiting
- Sponsor
- VA Office of Research & Development
- Start
- Mar 2024
- Primary completion
- Feb 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab in non-small cell lung cancer (NSCLC), sponsored by VA Office of Research & Development. Primary endpoints: Progression-free survival at 2 years and Treatment Tolerance at 3 years. Started Mar 2024; status: recruiting.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06275360.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06275360.